| Nov 6 |
CytomX Q3 2024 Earnings Preview
|
| Oct 31 |
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
|
| Sep 9 |
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
|
| Sep 4 |
CytomX Therapeutics to Present at Upcoming September Investor Conferences
|
| Aug 10 |
CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Aug 9 |
CytomX Therapeutics files $250M mixed securities shelf
|
| Aug 9 |
CytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
CytomX Therapeutics: Q2 Earnings Snapshot
|
| Aug 8 |
CytomX GAAP EPS of -$0.08 misses by $0.01, revenue of $25.11M beats by $5.12M
|
| Aug 8 |
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
